These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35272874)

  • 1. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
    Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
    J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Giant prolactinomas in men: efficacy of cabergoline treatment.
    Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
    Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men.
    Chattopadhyay A; Bhansali A; Masoodi SR
    Pituitary; 2005; 8(2):147-54. PubMed ID: 16379032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistant prolactinomas: a case series of 26 patients.
    Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
    Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men.
    Shimon I; Benbassat C; Hadani M
    Eur J Endocrinol; 2007 Feb; 156(2):225-31. PubMed ID: 17287412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review.
    Huang HY; Lin SJ; Zhao WG; Wu ZB
    Metab Brain Dis; 2018 Jun; 33(3):969-976. PubMed ID: 29546691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
    Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
    Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
    Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
    J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
    Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
    Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, Hormonal, and Neuroradiological Characteristics and Therapeutic Outcomes of Prolactinomas in Children and Adolescents at a Single Center.
    Yang A; Cho SY; Park H; Kim MS; Kong DS; Shin HJ; Jin DK
    Front Endocrinol (Lausanne); 2020; 11():527. PubMed ID: 32849307
    [No Abstract]   [Full Text] [Related]  

  • 13. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
    Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
    Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Women with prolactinomas presented at the postmenopausal period.
    Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
    Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
    Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
    Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotype and resistance patterns of 10 resistant prolactinomas.
    Araujo-Castro M; Abad López A; Aller Pardo J; Kanaan Kanaan L; Palacios García N
    Endocrinol Diabetes Nutr (Engl Ed); 2020 Mar; 67(3):194-204. PubMed ID: 31201099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Dopamine Agonist-Resistant Prolactinoma.
    Maiter D
    Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.